Median survival in months (95% confidence interval) according to the specific therapy administered
| . | Patients without t(11;14) . | t(11;14)(q13;q32) . |
|---|---|---|
| Patient receiving interferon versus other | 37.2 (33.9-44.1) | 51.2 (20.3-87.8) |
| 40.6 (34.7-47.2) | 49.3 (34.1-59.8) | |
| Log-rank | P > .2 | P > .2 |
| Patients receiving cyclophosphamide versus others | 38.8 (33.4-48.7) | 54 (24.5-71.2) |
| 38.7 (34.8-43.7) | 49.3 (34.1-61.4) | |
| Log-rank | P > .2 | P > .2 |
| . | Patients without t(11;14) . | t(11;14)(q13;q32) . |
|---|---|---|
| Patient receiving interferon versus other | 37.2 (33.9-44.1) | 51.2 (20.3-87.8) |
| 40.6 (34.7-47.2) | 49.3 (34.1-59.8) | |
| Log-rank | P > .2 | P > .2 |
| Patients receiving cyclophosphamide versus others | 38.8 (33.4-48.7) | 54 (24.5-71.2) |
| 38.7 (34.8-43.7) | 49.3 (34.1-61.4) | |
| Log-rank | P > .2 | P > .2 |